The end of the exclusive distributor reshapes UAE pharma market access and deal-making.

In February 2026 the Emirates Drug Establishment moved to end the single-agent model, requiring companies to appoint more than one authorised agent for each medical product marketed in the UAE. Medical products is the wider defined term: it reaches devices and biologicals, not only pharmaceuticals. The step was announced on 24 February 2026 and rests on Federal Decree-Law No. 38 of 2024 on medical products, pharmacists and pharmaceutical establishments. Implementing guidance on registration mechanics and agent responsibilities has not been published. The duty itself is neither new nor optional: Article 22 of the decree-law already requires a marketing authorisation holder to appoint at least two importers, and the law's one-year grace period expired on 2 January 2026. What is pending is the executive regulation, not the obligation. The commercial signal is already plain. Value that manufacturers and distributors built on locked, exclusive agencies is being repriced.

Since late December 2025 the EDE has taken 44 regulatory services from MOHAP in full, with a further 13 shared between them and 5, all narcotics-related, kept by the ministry. The 44 include marketing authorisation, product registration, variations, import and export permits, GMP oversight and pharmacovigilance. Community and compounding pharmacies remain with MOHAP. The body that registers your product and the body that will enforce multi-agent appointments are now one federal regulator. For any manufacturer whose UAE revenue runs through a registration held or effectively controlled by a single distributor, that concentration of authority changes the balance of power in your next negotiation.

For years a local agent's enterprise value rested heavily on tied exclusive registrations that a manufacturer could not easily move. Break the one-agent rule and that intangible thins out. A distributor whose valuation assumes perpetual exclusivity over a portfolio of principal brands is now carrying a number the market will question. Manufacturers gain a lever they have wanted for a long time: the ability to appoint a second agent, benchmark performance and reallocate volume without surrendering the registration itself.

When exclusivity no longer guarantees the flow, distributors compete on what is hard to replicate. Cold chain that meets good distribution practice for biologics and advanced therapies, standing hospital and formulary relationships, and a track record on government tenders become the assets that hold and win volume. Agents built on a paper monopoly with thin logistics behind it are the most exposed. Those with real infrastructure can take share from principals looking to add a second, more capable partner.

Every UAE agency agreement should be read now against the coming rules. Exclusivity grants, minimum-purchase commitments, termination triggers, registration ownership and data-access clauses all need testing for whether they survive a multi-agent requirement, and for the leverage they hand each side once the guidance lands. Waiting for the final regulations before opening the file cedes the initiative to whichever counterparty prepares first. The registration itself is the asset to protect, so where a distributor currently holds it in its own name, moving to a manufacturer-controlled or shared structure is the first order of business. Manufacturers who map their appointment strategy early will set terms; those who react will accept them.

A sub-scale agent holding a handful of exclusive lines, without the cold-chain, hospital or tender depth to compete on service, is a natural target or a natural seller. Expect strategic buyers and family offices to look hard at distributors with genuine infrastructure and multi-emirate reach, and to discount those whose value was only ever the exclusivity. The reform rewards scale and capability, and it punishes agents who mistook a contract clause for a business.

The EDE has signalled direction without yet setting the date, which is exactly the window to act. Manufacturers should model their agent structure, distributor shortlist and registration control now. Distributors should stress-test their portfolio for exclusivity risk and decide whether to buy capability, sell into strength or partner. Investors should be pricing both sides of this shift while the market is still working out what the assets are worth.